Figure 1.
Levels of palmitoylethanolamide (PEA) in plasma (panel A), hippocampus (panel B) and prefrontal cortex (panel C) of non-Tg mice 1, 1.5, 3, and 4 hours after oral administration (by gavage) of 100 mg/kg ultramicronized palmitoylethanolamide (um-PEA) or its vehicle [water/PEG/Tween-80 (90/5/5 ratio), v/v)]. Data are means ± SEM of five animals for each group. * p < 0.05; ** p < 0.01 significantly different from the respective vehicle time-point (Student t-test).